These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 25289657

  • 41. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia.
    Gharbiya M, Cruciani F, Parisi F, Cuozzo G, Altimari S, Abdolrahimzadeh S.
    Br J Ophthalmol; 2012 Aug; 96(8):1068-72. PubMed ID: 22661650
    [Abstract] [Full Text] [Related]

  • 42. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F.
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [Abstract] [Full Text] [Related]

  • 46. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.
    Munk MR, Rückert R, Zinkernagel M, Ebneter A, Wolf S.
    Expert Opin Biol Ther; 2016 Sep; 16(4):477-87. PubMed ID: 26666589
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 49. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.
    Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Osoba O, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Andrews C, Brittain C, Osborne A, Yang Y.
    Ophthalmology; 2013 Sep; 120(9):1944-5.e1. PubMed ID: 24001532
    [No Abstract] [Full Text] [Related]

  • 50. Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization.
    Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y.
    Acta Ophthalmol; 2009 Jun; 87(4):460-3. PubMed ID: 18479492
    [Abstract] [Full Text] [Related]

  • 51. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis.
    Hu J, Hoang QV, Chau FY, Blair MP, Lim JI.
    Retin Cases Brief Rep; 2014 Jun; 8(1):24-9. PubMed ID: 25372202
    [Abstract] [Full Text] [Related]

  • 52. [Intravitreal injection of bevacizumab for naive myopic choroidal neovascularization: 19-month results].
    De Bats F, Grange JD, Denis P, Kodjikian L.
    J Fr Ophtalmol; 2013 Jan; 36(1):12-8. PubMed ID: 23219506
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
    Roh MI, Kim HS, Song JH, Lim JB, Kwon OW.
    Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
    [Abstract] [Full Text] [Related]

  • 55. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence?
    Lai TY.
    Retina; 2012 Sep; 32(8):1443-5. PubMed ID: 22922844
    [No Abstract] [Full Text] [Related]

  • 56. Macular choroidal volume variations in highly myopic eyes with myopic traction maculopathy and choroidal neovascularization.
    Barteselli G, Lee SN, El-Emam S, Hou H, Ma F, Chhablani J, Conner L, Cheng L, Bartsch DU, Freeman WR.
    Retina; 2014 May; 34(5):880-9. PubMed ID: 24217703
    [Abstract] [Full Text] [Related]

  • 57. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
    Tewari A, Dhalla MS, Apte RS.
    Retina; 2006 May; 26(9):1093-4. PubMed ID: 17151505
    [No Abstract] [Full Text] [Related]

  • 58. Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study.
    Ueda-Consolvo T, Shibuya N, Oiwake T, Abe S, Numata A, Honda Y, Yanagisawa S, Hayashi A.
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3295-3303. PubMed ID: 34142188
    [Abstract] [Full Text] [Related]

  • 59. Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization.
    Huang J, Chen T, Lu Y, Long L, Dai H.
    Chin Med J (Engl); 2014 Nov; 127(11):2053-7. PubMed ID: 24890151
    [Abstract] [Full Text] [Related]

  • 60. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
    Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R.
    Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.